Compare · IRD vs NVO
IRD vs NVO
Side-by-side comparison of Opus Genetics Inc. (IRD) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IRD and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.82B, about 584.8x IRD ($328.0M).
- NVO has been more active in the news (8 items in the past 4 weeks vs 7 for IRD).
- NVO has more recent analyst coverage (25 ratings vs 12 for IRD).
- Company
- Opus Genetics Inc.
- Novo Nordisk A/S
- Price
- $3.97-1.98%
- $41.90-2.43%
- Market cap
- $328.0M
- $191.82B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 7
- 8
- Recent ratings
- 12
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest IRD
- SEC Form S-3 filed by Opus Genetics Inc.
- Guggenheim initiated coverage on Opus Genetics with a new price target
- Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts
- Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference
- Leerink Partners initiated coverage on Opus Genetics with a new price target
- Director Foundation Fighting Blindness Retinal Degeneration Fund sold $7,395,000 worth of shares (1,700,000 units at $4.35) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Opus Genetics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Opus Genetics Inc.
- SEC Form S-8 filed by Opus Genetics Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care